1
/
of
2
Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutic
Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutic
Regular price
$50.00 USD
Regular price
$0.00 USD
Sale price
$50.00 USD
Unit price
/
per
Tax included.
Shipping calculated at checkout.
Couldn't load pickup availability
Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics (Cancer Drug Discovery and Development)
2004th Edition
George Morstyn
Editor
MaryAnn Foote
Editor
Graham J. Lieschke
Editor
Leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and nonhodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem cell factor and its receptor, C-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonis
2004th Edition
George Morstyn
Editor
MaryAnn Foote
Editor
Graham J. Lieschke
Editor
Leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and nonhodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem cell factor and its receptor, C-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonis
Share
